BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang LM, Zhang Y, Fei C, Zhang J, Wang L, Yi ZW, Gao G. Neutralization of IL-18 by IL-18 binding protein ameliorates bleomycin-induced pulmonary fibrosis via inhibition of epithelial-mesenchymal transition. Biochem Biophys Res Commun 2019;508:660-6. [PMID: 30527805 DOI: 10.1016/j.bbrc.2018.11.129] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 3.3] [Reference Citation Analysis]
Number Citing Articles
1 Artlett CM. The Mechanism and Regulation of the NLRP3 Inflammasome during Fibrosis. Biomolecules 2022;12:634. [DOI: 10.3390/biom12050634] [Reference Citation Analysis]
2 Camiolo MJ, Zhou X, Wei Q, Trejo Bittar HE, Kaminski N, Ray A, Wenzel SE. Machine learning implicates the IL-18 signaling axis in severe asthma. JCI Insight 2021;6:e149945. [PMID: 34591794 DOI: 10.1172/jci.insight.149945] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
3 Scott TE, Qin CX, Drummond GR, Hobbs AJ, Kemp-Harper BK. Innovative Anti-Inflammatory and Pro-resolving Strategies for Pulmonary Hypertension: High Blood Pressure Research Council of Australia Award 2019. Hypertension 2021;78:1168-84. [PMID: 34565184 DOI: 10.1161/HYPERTENSIONAHA.120.14525] [Reference Citation Analysis]
4 Kaur D, Chachi L, Gomez E, Sylvius N, Brightling CE. Interleukin-18, IL-18 binding protein and IL-18 receptor expression in asthma: a hypothesis showing IL-18 promotes epithelial cell differentiation. Clin Transl Immunology 2021;10:e1301. [PMID: 34194747 DOI: 10.1002/cti2.1301] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Nakanishi Y, Horimasu Y, Yamaguchi K, Sakamoto S, Masuda T, Nakashima T, Miyamoto S, Iwamoto H, Ohshimo S, Fujitaka K, Hamada H, Hattori N. IL-18 binding protein can be a prognostic biomarker for idiopathic pulmonary fibrosis. PLoS One 2021;16:e0252594. [PMID: 34086758 DOI: 10.1371/journal.pone.0252594] [Reference Citation Analysis]
6 Fathimath Muneesa M, Shaikh SB, Jeena TM, Bhandary YP. Inflammatory mediators in various molecular pathways involved in the development of pulmonary fibrosis. Int Immunopharmacol 2021;96:107608. [PMID: 33857801 DOI: 10.1016/j.intimp.2021.107608] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 She YX, Yu QY, Tang XX. Role of interleukins in the pathogenesis of pulmonary fibrosis. Cell Death Discov 2021;7:52. [PMID: 33723241 DOI: 10.1038/s41420-021-00437-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
8 Venosa A, Gow JG, Taylor S, Golden TN, Murray A, Abramova E, Malaviya R, Laskin DL, Gow AJ. Myeloid cell dynamics in bleomycin-induced pulmonary injury in mice; effects of anti-TNFα antibody. Toxicol Appl Pharmacol 2021;417:115470. [PMID: 33647319 DOI: 10.1016/j.taap.2021.115470] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
9 Peng L, Wen L, Shi QF, Gao F, Huang B, Meng J, Hu CP, Wang CM. Scutellarin ameliorates pulmonary fibrosis through inhibiting NF-κB/NLRP3-mediated epithelial-mesenchymal transition and inflammation. Cell Death Dis 2020;11:978. [PMID: 33188176 DOI: 10.1038/s41419-020-03178-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 34] [Article Influence: 3.5] [Reference Citation Analysis]
10 Huang J, Tong X, Zhang L, Zhang Y, Wang L, Wang D, Zhang S, Fan H. Hyperoside Attenuates Bleomycin-Induced Pulmonary Fibrosis Development in Mice. Front Pharmacol 2020;11:550955. [PMID: 33192501 DOI: 10.3389/fphar.2020.550955] [Cited by in Crossref: 6] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
11 Mansour SM, El-Abhar HS, Soubh AA. MiR-200a inversely correlates with Hedgehog and TGF-β canonical/non-canonical trajectories to orchestrate the anti-fibrotic effect of Tadalafil in a bleomycin-induced pulmonary fibrosis model. Inflammopharmacology 2021;29:167-82. [PMID: 32914382 DOI: 10.1007/s10787-020-00748-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
12 Alyaseer AAA, de Lima MHS, Braga TT. The Role of NLRP3 Inflammasome Activation in the Epithelial to Mesenchymal Transition Process During the Fibrosis. Front Immunol 2020;11:883. [PMID: 32508821 DOI: 10.3389/fimmu.2020.00883] [Cited by in Crossref: 15] [Cited by in F6Publishing: 34] [Article Influence: 7.5] [Reference Citation Analysis]
13 Pinar AA, Scott TE, Huuskes BM, Tapia Cáceres FE, Kemp-harper BK, Samuel CS. Targeting the NLRP3 inflammasome to treat cardiovascular fibrosis. Pharmacology & Therapeutics 2020;209:107511. [DOI: 10.1016/j.pharmthera.2020.107511] [Cited by in Crossref: 25] [Cited by in F6Publishing: 21] [Article Influence: 12.5] [Reference Citation Analysis]
14 Mühl H, Bachmann M. IL-18/IL-18BP and IL-22/IL-22BP: Two interrelated couples with therapeutic potential. Cell Signal 2019;63:109388. [PMID: 31401146 DOI: 10.1016/j.cellsig.2019.109388] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
15 Romeo E, Caserta CA, Rumio C, Marcucci F. The Vicious Cross-Talk between Tumor Cells with an EMT Phenotype and Cells of the Immune System.Cells. 2019;8. [PMID: 31096701 DOI: 10.3390/cells8050460] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 11.7] [Reference Citation Analysis]
16 Zhang LM, Zhang J, Zhang Y, Fei C, Wang L, Yi ZW, Zhang ZQ. Interleukin-18 promotes fibroblast senescence in pulmonary fibrosis through down-regulating Klotho expression. Biomed Pharmacother 2019;113:108756. [PMID: 30870716 DOI: 10.1016/j.biopha.2019.108756] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]